Market Overview

Aratana Therapeutics Acquires Okapi Sciences NV

Aratana Therapeutics (NASDAQ: PETX) today announced that it has acquired Okapi Sciences NV, a Belgium-based company with a proprietary pet therapeutics antiviral platform and five clinical/development stage candidates for treating important viral diseases.  The strategic acquisition of Okapi further enhances Aratana's leadership position in pet therapeutics by bringing with it a unique combination of individuals, strong relationships with academic institutions, novel technologies and products, and favorable geographic location.  Aratana plans to continue to advance the current Okapi pipeline of high value antiviral drugs, including its feline herpes and feline immunodeficiency virus franchises. 

See full press release

Posted-In: News Guidance Asset Sales Management M&A Global

 

Related Articles (PETX)

Around the Web, We're Loving...

Get Benzinga's Newsletters